EGFR and non-small cell lung carcinoma: The third-generation EGFR-TKI, osimertinib, was shown to be superior to the first-generation TKIs, gefitinib and erlotinib, in terms of progression-free survival (PFS) and overall survival (OS); therefore, it is now widely recommended as a first-line treatment for patients with NSCLC harboring EGFR mutations [22–25].